Arcutis and Padagis to pause patent lawsuit over Zoryve

IvelinRadkov/iStock via Getty Images Arcutis Biotherapeutics ( NASDAQ: ARQT ) shares rose on Wednesday after Padagis and its units requested a pause in an ongoing patent lawsuit related to ARQT's lead product, Zoryve, and both parties agreed to temporarily halt the case. As part of the agreement, Padagis.